$AKESO(09926.HK) rose by five or six points today, and $WUXI APPTEC(02359.HK) also saw a slight gain. The sentiment around Hong Kong's innovative drugs and CXO sectors has clearly returned—on days when the Hang Seng Index surges, innovative drug concepts are among the most active, with overseas licensing deals coming one after another, and capital willing to provide elasticity.

The US pharmaceutical sector is a different world: $Johnson & Johnson(JNJ.US) and $Recursion Pharmaceuticals(RXRX.US) both dipped slightly, while $Boston Scientific(BSX.US) and $Hims & Hers Health(HIMS.US) remained basically unchanged. Large-cap stocks aren't being front-run ahead of earnings season, and the AI drug narrative is waiting for new data.

Hong Kong stocks are trading on the "revaluation of Chinese innovative drugs," while US stocks are waiting for "guidance from the next earnings report." The pricing clocks on both sides are out of sync. The sustainability of this Hong Kong rally depends on the pace of licensing deals and medical insurance negotiations, not on the mood of US pharma.